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E-proteins define a distinct class of basic helix-
loop-helix transcription factors that are central 
regulators of cellular differentiation in various 
cell types and are essential for the development 
of B and T lymphocytes (Kee, 2009). There 
are  three  known  E-protein  coding  genes  in 
mammals, namely E2A (also called TCF3), E2-2 
(also  called  TCF4)  and  HEB  (HeLa  E-box 
binding protein; also called TCF12), which all 
bind to a DNA sequence motif called E-box 
(CANNTG). The E2A gene, which is located 
on chromosome 19p13.3, encodes for two dif-
ferent basic helix-loop-helix transcription fac-
tors, E12 and E47, which are generated by 
alternative splicing (Mellentin et al., 1989; 
Murre et al., 1989). E2A proteins form homo-
dimers  and  heterodimers  with  other  HLH 
proteins to conduct their tissue- or cell type–
specific functions (Kee, 2009).
Alterations of E2A expression and activity 
have been suggested to support malignant trans-
formation of lymphoid cells. In mice, deletion 
of E2A, as well as enforced expression of its   
inhibitors, e.g., the inhibitor of DNA binding 
(Id)  proteins,  lead  to  rapid  development  of   
aggressive T cell lymphomas and T cell hyper-
proliferations  (Bain  et  al.,  1997;  Yan  et  al., 
1997; Morrow et al., 1999). In humans, di-
minished E2A activity has been proposed as a 
pathogenetic  mechanism  in  TAL1/SCL-  or 
E2A-PBX1–induced  leukemias  (Park  et  al., 
1999; Aspland et al., 2001; O’Neil et al., 2004), 
and functional blockade of E2A is involved in 
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The transcription factor E2A is essential for lymphocyte development. In this study, we 
describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome 
(SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell 
cycle progression via derepression of the protooncogene MYC and the cell cycle regulator 
CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration 
of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic 
signaling pathways, including the Ras pathway. Several of these genes are down-regulated 
or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of 
E2A in human lymphoid cells and could help to develop new treatment strategies for 
human lymphomas with altered E2A activity.
©  2011  Steininger  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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activity by immunoblotting and electrophoretic mobility shift 
assay. In both analyses, we reached levels comparable to en-
dogenous ones in other T cell leukemia–derived cell lines 
(Fig. S3 C). To substantiate our finding of reduced prolifera-
tion after E2A reconstitution, we measured DNA synthesis 
(determined by BrdU incorporation) and the respective cell 
cycle phases (determined by 7-aminoactinomycin D [7-AAD] 
staining) in parallel by a two-color flow cytometric analysis 
(Fig. 2 B). This experimental approach revealed that reexpres-
sion of E2A in Se-Ax cells significantly increased the fraction of 
cells in the G0/G1 phase at the expense of cells in the S phase 
of the cell cycle, suggesting that the reduced proliferation   
of Se-Ax cells after E2A reconstitution is caused by a G0/G1 
cell cycle arrest.
To establish a mechanistic link between E2A reduction 
and deregulated cell cycle control, we analyzed mRNA ex-
pression of the protooncogene MYC and the cell cycle regu-
lator CDK6 in Se-Ax cells. After E2A reconstitution, we 
observed significantly reduced mRNA levels of both genes 
(Fig. 2 C), suggesting a pathogenetically relevant link in these 
human T cell–derived lymphoma cells. In line with these in 
vitro data, we observed robust protein expression of CDK6 
in 7 out of 7 and, in accordance with previously published 
data (Vermeer et al., 2008), of MYC in 5 out of 6 primary SS 
tumor samples (Fig. 2 D). The high level of MYC expression 
in the SS tumor cells is in the majority of our SS cases most 
likely supported by genomic gains of chromosome 8q, which 
also includes the MYC locus (Fig. S1 and Table S4). Notably, 
the MYC-induced apoptotic program (Eischen et al., 1999) 
might be counteracted by the loss of 17p, including the tumor 
suppressor gene TP53, as demonstrated in a large number of   
our SS patient samples (Table S4).
To further investigate the impact of diminished E2A ex-
pression on SS tumor cells, we characterized E2A-dependent 
transcriptional changes in Se-Ax cells by microarray gene 
expression analyses. A highly overlapping, limited number   
of  genes  were  responsive  to  E2A  reconstitution  with   
either E47 or E47-FD (Fig. S3 D and Table S5). Overall,   
far more genes were induced than repressed. Arguing for   
the  biological  relevance  of  our  microarray  analyses,  the 
E2A-regulated genes in our data showed a significant over-
lap with E2A-dependent genes identified in E2A-deficient 
murine T cell lymphoma (Schwartz et al., 2006) and in a 
murine E2A-deficient hematopoietic progenitor cell line 
(Ikawa et al., 2006; Fig. S3 E and Table S6). In our dataset, 
among  the  E2A-induced  genes  were  proapoptotic  genes 
like BCL2L11 and BIK, genes known to modulate T cell–
specific  signaling  pathways  and  differentiation  (DTX1, 
MAL), as well as negative regulators of oncogenic signaling 
pathways including the Ras signaling pathway (RASSF4, 
DAB2IP, RASA4, RGS16). The E2A-dependent up-regulation 
of these genes was confirmed by quantitative PCR (Fig. 3 A). 
In  view  of  their  dependency  on  E2A,  expression  would   
be  expected  to  be  down-regulated  or  lost  in  SS  tumor   
cells because of their reduced E2A expression. Accordingly,   
BCL2L11 and MAL were previously described to be specifically 
the pathogenesis of human lymphomas (Mathas et al., 2006, 
2009; Lietz et al., 2007). However, a frequent genomic loss 
of E2A has not been identified in human lymphoid malig-
nancies so far. Arguing for a function as tumor suppressor in 
human cells, our study now demonstrates a recurrent dele-
tion of E2A in leukemic cells of patients suffering from Sézary 
syndrome (SS), an aggressive variant of primary cutaneous   
T cell lymphoma characterized by the presence of neoplastic 
T cells in skin, lymph nodes, and peripheral blood (Willemze   
et al., 2005).
RESULTS AND DISCUSSION
In a genome-wide analysis of peripheral blood mononuclear 
cells from 20 SS patients (Table S1) by array comparative 
genomic hybridization (array CGH), we identified a mini-
mal common region of chromosomal loss on chromosome 
19p13.3 in 70% (14/20) of patients (Fig. 1 A, Table I, Fig. S1, 
and Table  S2).   This  region  of  1.4  Mb  ranging  from 
chr19:1368087 to chr19:2824434 (HG18) included the E2A 
gene locus. Fluorescence in situ hybridization (FISH) analy-
sis on highly enriched tumor cells using an E2A-specific 
probe confirmed a heterozygous loss of E2A in 8/12 ana-
lyzed SS patient samples (Fig. 1 B and Table I; for details on 
tumor cell enrichment see Materials and methods, Fig. S2, 
and Table S3). The number of cases with E2A deletion might 
even be underestimated because in two cases without dele-
tion in array CGH analysis, a deletion of E2A was detected 
by FISH (Table I). Concomitant with the genomic loss of 
E2A, the E2A mRNA expression level in enriched leuke-
mic cells of SS patients was significantly reduced compared 
with purified CD4+ T cells from healthy volunteers (Fig. 1 C 
and Fig. S3 A; note, that the Ct of E12/E47 or E47, re-
spectively, is significantly lower in CD4+ controls compared 
with SS patient samples. Hence, relative to GAPDH, SS   
patient  samples  express  less  E12/E47  or  E47  mRNA,   
respectively, than the control CD4+ T lymphocytes), and   
immunohistochemistry showed weak or absent E2A protein 
expression in skin-infiltrating tumor cells in 15/15 patient 
samples (Fig. 1 D).
Among cutaneous T cell lymphomas, SS is unique in re-
spect to the presence of a high load of lymphoma cells in the 
peripheral blood. Because E2A interferes with cell cycle con-
trol (Park et al., 1999; Murre, 2005), we first investigated the 
impact of reduced E2A expression on the growth of malignant 
SS cells. To this end, we chose the SS-derived Se-Ax cell line, 
which is associated with a heterozygous loss of E2A (Fig. 1 B   
and Table I) and is characterized by reduced E2A mRNA and 
protein levels and impaired E-box DNA binding activity (Fig. 1, 
E and F and Fig. S3 B). After transient transfection with a 
Myc-tagged E47 construct and, alternatively, a construct cod-
ing for two covalently linked E47 molecules (E47-forced dimer, 
E47-FD),  Se-Ax  cells  showed  a  pronounced  reduction  of 
proliferation (Fig. 2 A). No significant effect on apoptosis in-
duction was observed (unpublished data). To prove the bio-
logical significance of our transfection approach, we investigated 
transgene expression as well as the resulting E2A-DNA binding JEM Vol. 208, No. 8  1587
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samples, whereas reduced levels of RGS16 were observed   
in 2/4 SS samples compared with normal CD4+ T cells   
(Fig. 3, B and C).
down-regulated in SS cells (Kari et al., 2003; van Doorn   
et al., 2004). In our samples, BCL2L11, DTX1, and RASSF4 
were found to be down-regulated in 4/4 of our SS patient 
Figure 1.  Loss of E2A is a common feature in SS tumor cells. (A) Array CGH results for chromosome 19 in tumor cells of 14 SS patients. The 
frequency of chromosomal gains and losses in percent of studied cases is shown to the right and to the left of the chromosome idiogram, respec-
tively. The genomic interval ranging from chr19: 200000–8599999 (HG18) is enlarged in the adjacent heatmap to the left. The coloring of each box 
in this heatmap represents the average array CGH ratio based on a 100-kb window for those 14 cases harboring E2A deletions according to CGH 
results. Chromosomal deletions and gains are shown in red and green, respectively (maximal color saturation at a log2 ratio of 0.6/0.6). The  
arrow indicates the genomic position of E2A. (B) Dual-color FISH analyses of purified tumor cells (patients #9 and #4) and the SS-derived cell line 
Se-Ax. Cells were hybridized with an E2A probe (red) and a control probe on 19qter (green). Pictures show representative examples of tumor cells 
without E2A deletion (Pat. #9: two red signals/two green signals) and cells with heterozygous deletion of the gene locus (Pat. #4, one red/two 
green; Se-Ax cells, two red/three green signals). Bars, 5 µm. (C) Quantification of E2A mRNA levels by real-time PCR in CD4+ T lymphocytes from 
healthy volunteers and purified leukemic SS cells from various patients, as indicated. (left) E2A mRNA expression in the various samples was ana-
lyzed relative to GAPDH by quantitative real-time PCR using primers recognizing both E2A splice variants, E12 and E47. (right) Box plot presenta-
tion of the comparison of Ct values of E2A in CD4+ controls (six male [CD4 #m] and six female [CD4 #f] samples) and SS patient samples (Pat. #). 
Results are shown for one of two independent experiments performed. (D) Immunohistochemistry of SS skin biopsies. Shown is double staining of 
the T cell marker CD3 (brown) and E12/E47 (purple). Dashed circle designates accumulations of malignant lymphocytes in the epidermis, so called 
Pautrier’s microabscesses. Arrows point to individual tumor cells with cerebriform nuclei. Bars, 50 µm. (E and F) E2A expression and DNA binding 
activity in various cell lines. (E, top) RT-PCR analysis of E2A mRNA expression in T cell–derived control cell lines Molt-14, Jurkat, and KE-37, as well 
as SS-derived Se-Ax cells. (bottom) Analysis of E2A protein expression in nuclear extracts of various cell lines by Western blotting (WB) using anti-
bodies to both E2A splice variants E12 and E47 (E12/E47) or to E47. GAPDH and PARP were analyzed as controls. Results are shown for one of 
three independent experiments performed. (F) EMSA of E2A DNA-binding activity in the various cell lines, as indicated. Sp1 DNA binding was ana-
lyzed as a control. Positions of the specific protein–DNA complexes are indicated. n.s., nonspecific complex. Results are shown for one of three 
independent experiments performed.1588 Loss of E2A in human lymphoma | Steininger et al.
likely  by  loss  of  transcriptional  repression.  Speculations   
on  the  interconnection  of  MYC,  E2A,  and TP53  and   
their synergistic influence on lymphoma development are 
substantiated by the high number of cases with simultane-
ous DNA copy number changes affecting these genes in 
our SS samples, as well as in E2A-deficient lymphoma cells 
in mice, a fact that most likely reflects the selective advan-
tage provided by the combination of these aberrations (Fig. S1 
and Table S4; Bain et al., 1997). Up-regulation of CDK6 as 
a consequence of reduced E2A levels could represent an-
other strategy of SS cells to provide a growth and survival 
advantage. Higher levels of CDK6 in SS cells might co-
operate with an aberrant activation of the NOTCH signal-
ing  pathway,  because  CDK6  is  necessary  to  exert  the 
proliferative and anti-apoptotic function of NOTCH (Hu 
et al., 2009). NOTCH itself promotes T lymphomagenesis 
(Koch and Radtke, 2007) and is required for the survival of 
E2A-deficient lymphoma cells in mice (Reschly et al., 2006). 
In line with this concept, NOTCH activation has been re-
ported in SS cells (Kamstrup et al., 2010). In addition, our data 
show that E2A controls negative regulators of the oncogenic 
Apart from their central role in B and T lymphocyte 
development, E2A proteins have been suggested to act as 
tumor suppressors (Bain et al., 1997; Yan et al., 1997). Al-
though other genes located at 19p13.3 might also contrib-
ute to the pathogenesis of SS, our data identify the loss of 
E2A as a pathogenetically important defect of SS tumor 
cells and strongly support a role of E2A as a tumor suppres-
sor in human lymphoid cells. Mechanistically, we provide 
evidence that E2A controls a whole set of genes known to 
promote  tumorigenesis.  Concomitant  with  an  increased 
proliferation rate, most likely caused by an impaired G0/G1 
cell cycle checkpoint, loss of E2A resulted in an up-regulation 
of MYC and CDK6. Both genes have been described as 
E2A  target  genes  in  lymphomas  that  emerge  in  E2A-
  deficient mice (Schwartz et al., 2006) and are known to be 
involved in lymphocyte proliferation, survival, and differ-
entiation (Herold et al., 2009; Hu et al., 2009). Further-
more, aggressive T cell lymphomas in E2A-deficient mice 
are characterized by high-level myc expression (Bain et al., 
1997). This suggests that up-regulation of the MYC onco-
gene is a common phenomenon after loss of E2A, most 
Table I.  Loss of E2A in SS tumor cells
Patient no. Loss of E2A Purity of enriched tumor 
cells Array CGH analysis FISH analysis (number of cells with deletion/number  
of analyzed cells)
%
1 yesc yes (149/200)e 96.7
2 yesc n.d –
3 yesc yes (198/200)e 99.1
4a yesc yes (167/200)e 93.2
5 yese yes (90/200)e 97.9
6 yesd n.d. –
7a yesc no (14/200)e 99.2f
8 yese n.d. –
9 noc no (3/200)e 97.4
10 noc no (4/200)e 96.9
11a yese no (12/200)d n.d.
12 noc n.d. –
13 yesc yes (126/200)e 98.4f
14 noc n.d. –
15a nob,c yes (106/200)d n.d.
16a noe yes (loss 28/200, gain 46/200)e 97.2
17 yese yes (50/200)e 98.4
18 yesc n.d. –
19 yese n.d. –
20 yese n.d. –
Se-Ax cell line yes yes (190/200)
 n.d.: not determined
aCGH and FISH analyses were performed with samples from different time points (see Table S1).
bhypotriploid cells, gain of chromosome 19 except 19p13.2-13.3. 
cAnalysis of PBMC cells.
dAnalysis of CD4-sorted cells.
eAnalysis of V-sorted cells. 
fPurity was determined with CD4 antibody only.JEM Vol. 208, No. 8  1589
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E2A dosage might facilitate the posttranslational degrada-
tion of E2A by NOTCH1 (Nie et al., 2003), which is aber-
rantly activated in SS cells (Kamstrup et al., 2010). Such a 
model, i.e., that lowering of wild-type E2A expression con-
tributes to human lymphomagenesis, is supported by the 
finding of aberrant up-regulation of E2A antagonists like 
inhibitory HLH proteins (O’Neil et al., 2004; Lietz et al., 
2007; Mathas et al., 2006, 2009) or the disruption of one 
E2A allele and maintenance of one wild-type allele as a re-
sult of translocations involving the E2A locus (Aspland et al., 
2001) in human lymphoma cells. That even a subtle dosage 
reduction of a putative tumor suppressor is sufficient for   
tumor formation has recently been formally shown for, e.g., 
PTEN (Alimonti et al., 2010).
Together, our data highlight the genomic loss of 19p13.3 
including the E2A locus as a pathogenetically important de-
fect of human T cell–derived SS lymphoma cells. Our results 
provide insights into how E2A acts as a tumor suppressor in 
human lymphoid cells and might help to develop new treat-
ment strategies for human lymphomas with lost or reduced 
E2A activity.
Ras signaling pathway (RASSF4, RASA4, and DAB2IP). 
Although altered expression of each of these genes alone 
might result in Ras activation (Eckfeld et al., 2004; Lockyer 
et al., 2001; Min et al., 2010), activation of the Ras signaling 
pathway has still to be proven formally in SS cells. There-
fore, the therapeutic potential of Ras inhibition in lympho-
mas with reduced E2A activity has to be investigated in 
future studies.
By FISH analysis, no homozygous deletion of E2A was 
observed. Direct sequencing of the coding regions of all 
E2A exons in leukemic SS cells from 13 patients did not re-
veal deleterious mutations or deletions (Table S7). Further-
more, the investigated E2A promoter regions in enriched   
SS cells compared with normal CD4+ T cells did not show 
altered methylation patterns Fig. S4. These data suggest on the 
one hand that the reduction of E2A expression after mono-
allelic E2A deletion might be sufficient for lymphoma pro-
gression, and on the other hand that selective pressure exists 
to retain one E2A copy to ensure a certain level of E protein 
activity, which is probably necessary for cellular survival at 
some  time  point  during  lymphomagenesis.  Lowering  the 
Figure 2.  E2A-dependent proliferation 
and expression of MYC and CDK6 in SS 
cells. (A) Reconstitution of E2A expression in 
SS-derived Se-Ax cells. Se-Ax cells were 
transfected with Mock plasmid (control) or 
plasmids encoding Myc-tagged E47 (E47) or 
E47-FD, as indicated, along with pEGFP. 
EGFP+ cells were purified 48 h after transfec-
tion, pulsed with 1 µCi [3H]thymidine per well 
for another 20 h, and then [3H]thymidine 
incorporation was determined. Error bars 
denote standard deviation. Results are shown 
for one of three independent experiments 
performed. *, P < 0.001. (B) Proliferation and 
cell cycle analyses of Se-Ax cells after E2A 
reconstitution. Se-Ax cells were transfected 
as described in A. 48 h after transfection, 
cells were pulsed for 30 min with BrdU. 
Thereafter, transfected cells were gated based 
on their EGFP expression, and BrdU incorpo-
ration and 7-AAD staining was measured by 
flow cytometry in GFP+ cells. Left, represen-
tative examples for detection of BrdU incor-
poration and 7-AAD staining by flow 
cytometry in Mock- (top) or E47- (bottom) 
transfected Se-Ax cells. Positions and per-
centages of cells in cell cycle phases G0/G1, 
S, and G2/M are indicated. Right, summary  
of cell cycle analyses of Mock- vs. E47-FD– (top) 
and E47- (bottom) transfected Se-Ax cells. 
The fraction of cells in the respective cell 
cycle phases is indicated in percent. Error 
bars denote standard deviations. Results are shown for one of three independent experiments performed. *, P < 0.05; **, P < 0.005; NS, not significant. 
(C) Se-Ax cells were transfected with E47-FD and purified as described in A. Expression of MYC and CDK6 mRNA was assessed by quantitative PCR. 
Error bars denote 95% confidence intervals. Results are shown for one of three independent experiments performed. *, P < 0.001. (D) Representative 
MYC and CDK6 immunohistochemistry of each two SS skin biopsies. MYC and CDK6 stainings are in brown. Dashed circles designate Pautrier’s micro-
abscesses. CDK6, right, CDK6 expression in cells with frequent cerebriform nuclei within a dermal infiltrate from a patient with SS. Bars, 50 µm.1590 Loss of E2A in human lymphoma | Steininger et al.
Flow cytometric analysis of tumor cell samples. PBMCs and enriched 
tumor cells were analyzed on a FACSCalibur flow cytometer (BD) using 
CellQuest Pro software (BD) and WinMDI version 2.9 (The Scripps Research 
Institute). Antibodies directed against CD3, CD4, and CD8 were purchased 
from BD. All Vchain specific antibodies were from Beckman Coulter   
(see Table S3 for details).
Cell lines, culture conditions, proliferation, and cell cycle analysis. 
The human SS-derived cell line Se-Ax (Kaltoft et al., 1987); the T cell acute 
lymphoblastic leukemia (T-ALL) cell lines Molt-14, Jurkat, and KE-37; and   
H9 cells were cultured as previously described (Mathas et al., 2009), apart from 
adding 100 U/ml recombinant human IL-2 (Sigma-Aldrich) to Se-Ax cell cul-
ture medium. Se-Ax cells were electroporated in OPTIMEM I (Invitrogen)   
using a Gene-Pulser II (Bio-Rad Laboratories) with 500 F and 0.24 kV. Trans-
fection  efficiency  was  determined  by  pEGFP-N3  (Takara  Bio  Inc.)  co-
  transfection and subsequent flow cytometry. Cells were transfected with 30 µg 
myc-tagged E47 or E47-FD expression constructs (Sigvardsson et al., 1997; Lietz 
et al., 2007) or 30 µg control plasmid pcDNA3.1 (Invitrogen), along with 10 µg 
of pEGFP-N3. 48–72 h after transfection, EGFP+ cells were enriched by FACS 
sorting, and sorted cells were used for proliferation assays as well as RNA and 
protein preparation. Proliferation of cells was determined by measurement of 
DNA  synthesis  after  [3H]thymidine  incorporation  using  standard  protocols.   
Parallel measurement of BrdU incorporation for determination of proliferation 
and of 7-AAD staining for determination of cell cycle position was performed by 
use of the APC BrdU Flow kit (BD). In brief, 48 h after transfection, cells were 
pulsed for 30 min with BrdU, and BrdU incorporation and 7-AAD staining in 
gated EGFP+ cells was determined by flow cytometry.
Array CGH. Initial array CGH analysis was done by means of a submegabase 
resolution BAC array, as described previously (Erdogan et al., 2006). DNA copy 
number changes were defined by circular binary segmentation (Olshen et al., 
2004) in combination with a log2 threshold of 0.2/0.2. Aberrations encom-
passing chromosome arm 19p were further verified and fine-mapped by hybrid-
izations onto a 400k whole genome (Agilent; Gene Expression Omnibus [GEO] 
accession no. GPL9777) and a customized 60k chromosome 19p oligonucle-
otide array (Agilent; GEO accession no. GPL10304), respectively, following the 
manufacturer’s  recommendations  (Table  S8). The  customized  array  com-
prised 52,828 oligonucleotides evenly covering chromosomal region chr19:   
1–28,500,000 (NCBI36; HG18). Array CGH data discussed in this work are 
available (Barrett and Edgar, 2006) under GEO accession no. GSE19000.
MATERIALS AND METHODS
Patient samples. 20 clinically well-characterized patients with SS were in-
cluded in our study. Diagnoses were established according to the World Health 
Organization-European Organization for Research and Treatment of Cancer 
classification for cutaneous lymphomas (Willemze et al., 2005). Detailed clinical 
information on all patients and blood samples are summarized in Table S1. The 
use of human material was approved by the Local Ethics Committee of   
the Charité-Universitätsmedizin Berlin and performed in accordance with the   
Declaration of Helsinki.
Clonality analysis and sequencing of tumor cell–specific TCR 
rearrangements. PBMC samples were analyzed for the presence of a 
clonally expanded tumor cell population by TCR-rearrangement PCR 
analysis using primers and protocols developed within the BIOMED-2 
BMH4-CT98-3936 Concerted Action initiative (van Dongen et al., 2003). 
Only samples that showed almost single clonal product peaks in the fluo-
rescent fragment analysis (FFA) were directly used for subsequent CGH 
analysis. To identify the V chain expressed by the respective tumor cells, 
amplification products were purified and complete TCR rearrangements 
were sequenced using the BigDye Terminator V1.1 cycle sequencing kit 
(Applied Biosystems) and subsequent analysis by high resolution electro-
phoresis  on  an  ABI  PRISM  310  Genetic  Analyzer.  Identification  of   
the involved V, D, and J segments was done by submitting the received 
TCR sequence to the International Immunogenetics Information System   
V-QUEST tool (http://imgt.cines.fr/IMGT_vquest/share/textes/; Brochet 
et al., 2008; Lefranc et al., 2009). Results for each patient are presented   
in Table S3.
Enrichment of primary SS tumor cells from PBMCs. PBMCs were 
isolated from whole blood or leukapheresis samples by density gradient   
centrifugation using Ficoll-Paque-Plus (GE Healthcare). For enrichment 
of tumor cells, PBMCs were incubated for 30 min with the respective   
fluorochrome-conjugated V antibody (Beckman Coulter; see Table S3 for 
details) at a concentration of 5–20 µl/106 cells in 100 µl of MACS buffer, 
followed  by  incubation  with  anti-fluorochrome  MicroBeads  (Miltenyi 
Biotec). Cells were magnetically separated by use of LS columns (Miltenyi 
Biotec) according to the manufacturer’s recommendations. Where indi-
cated, tumor cells were enriched after incubation with anti-CD4 microbeads 
(Miltenyi  Biotec).  The  purity  of  enriched  cells  was  determined  by   
flow cytometry.
Figure 3.  E2A-regulated genes in SS tumor 
cells. (A) Se-Ax cells were transfected with 
Mock plasmids (control) or plasmids encoding 
E47-FD, along with pEGFP. 48 h after transfec-
tion, EGFP+ cells were enriched. Expression of 
various genes, as indicated, was assessed by 
quantitative PCR. Error bars denote 95%  
confidence intervals. Results are shown for  
one of four independent experiments per-
formed. *, P < 0.5; **, P < 0.01; ***, P < 0.001.  
(B and C) mRNA expression of various genes in 
purified CD4+ T cells from healthy donors (CD4 
#1 to CD4 #4) compared with enriched tumor 
cells derived from four SS patients (Pat. #2, #3, 
#4, #5; numbers refer to the same patients 
listed in Table I). If mRNA expression was de-
tectable in SS samples by semiquantitative PCR 
(B), mRNA expression was quantified by real-
time PCR in the respective samples (C). Error 
bars denote 95% confidence intervals. Results 
are shown for one of two independent experi-
ments performed.JEM Vol. 208, No. 8  1591
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and  as  5-CCTACCTCCCTTTGCAGGCT-3;  Exon  7,  s  5-GCA-
GGGGTTGTTCTCATGGC-3  and  as  5-AAGCTTCGCCAGGA-
CACAGG-3; Exon 8, s 5-GAAACGGGGTGGTAGATGTG-3 and as 
5-GAGGGGAGCTGGTAAGGTG-3;  Exon  9,  s  5-CTATCCC-
GCCCCCTTCTAC-3  and  as  5-GTTCACCTCTGCTCCATGC-3; 
Exon  10,  s  5-GCACGAGCGTATGGTAGGAC-3  and  as  5-CTCT-
CAGGGCCAGCAGAC-3;  Exon  11+12,  s  5-CTGTGCAGGACG-
GCAGAAC-3  and  as  5-CCGCAAAGCCTTCACAGA-3;  Exon  13,  s 
5-ATCAGGCCATGCTCACACCC-3  and  as  5-TCTGTCCTG-
CAAATTCTGTCGG-3; Exon 14, s 5-CATGCGGAAGGGACATGA-3 
and as 5-GGTGGCTGCCTCCAACCT-3; Exon 15, s 5-GCTGGCCT-
CAGGTTTCAC-3 and as 5-ACCCTGACCCCCACCACTA-3; Exon 
16a,  s  5-CCAAGACCTGGTTTTTCCAG-3  and  as  5-GAGGGAGA-
CAGTGAGGTTGG-3; Exon 16b, s 5-ACCCACACTGGGAGGCCGT-3 
and as 5-CAGTCATGGCAATGCGGTCA-3; Exon 17, s 5-TACC-
CTCTCCACAACCCAGC-3  and  as  5-AGCATCTGCACCTGGG-
TGTG-3; Exon 18, s 5-ACATCTTTCTCCTCCCTGGG-3 and as 
5-GTGTGGATGTGGATGAAGCC-3.
Bisulfite  pyrosequencing.  Bisulfite  pyrosequencing  of  two  amplicons   
located in the E2A promoter region was performed according to Lamprecht   
et al., 2010 with few modifications. In brief, genomic DNA was bisulfite 
converted using the EpiTect Bisulfite Conversion kit (QIAGEN). In a post-
PCR amplification, locus-specific primers were used with one primer bio-
tinylated at the 5 end (PCR and sequencing primer sequences and analyzed 
region are shown in the following paragraph). For E2A amplification reac-
tions, PyroMark PCR kit (QIAGEN) was used according to standard proto-
cols. After initial denaturation (95°C for 15 min), PCR consisted of 45 
cycles of 94°C for 30 s, annealing temperature for 30 s, and 72°C for 30 s, 
followed by a final synthesis at 72°C for 10 min. Pyrosequencing was per-
formed using the Pyrosequencer ID and the DNA methylation analysis soft-
ware Pyro Q-CpG 1.0.9 (Biotage), which was also used to evaluate the ratio 
T:C (mC:C) at the CpG sites analyzed. All assays were optimized and vali-
dated using commercially available completely methylated DNA (Millipore) 
and pooled DNA isolated from peripheral blood of 10 healthy male and fe-
male controls, respectively.
Primer  sequences  and  conditions  used  for  bisulfite-pyrosequencing 
were as follows: E2A_promA, s 5-TTAGTTTATGGAGGGTAGGTA-3  
(5  modification,  biotin)  and  as  5-AAACCCCAACAATATTCA-3 
(annealing temperature, 55°C; amplicon length, 126 bp; analyzed region 
[ucsc, HG18], chr19:1,601,941-1,602,066); E2A_promA_seq, 5-CCCTA-
AATTACTTTACTAT-3;  E2A_promB,  s  5-TAAGGGGGAAATTG-
AGGT-3  and  as  5-CCCTAATACTAAACCCTACATACAA-3  (5  mod-
ification, biotin; annealing temperature, 55°C; amplicon length, 139 bp;   
analyzed region [ucsc, HG18], chr19:1,596,870-1,597,008); E2A_promB_seq, 
5-ATTGAGGTTTTGGAG-3.
Electrophoretic mobility shift assay (EMSA) and immunoblotting. 
Preparation of whole-cell and nuclear extracts, as well as EMSA, was performed 
as previously described (Mathas et al., 2006). The following double-stranded   
oligonucleotides were used for EMSA: E2A (E5) sense  5-AGCTCCAGAA-
CACCTGCAGCAG-3 and E2A (E5) antisense, 5-AGCTCTGCTGCA-
GGTGTTCTGG-3; Sp1 sense, 5-AGCTATTCGATCGGGGCGGGGCG-
AGC-3  and  Sp1  antisense,  5-AGCTGCTCGCCCCGCCCCGATC-
GAAT-3. After annealing, oligonucleotides were end-labeled with [-32P]dCTP   
using Klenow fragment. Positions of protein–DNA complexes were visualized   
by autoradiography. For supershift analyses, mouse monoclonal antibody to 
E12/E47 (clone G98-271; BD) was used. For immunoblot analyses, the follow-
ing primary antibodies were used: mouse monoclonal antibody to E12/E47 
(clone G98-271; BD), mouse monoclonal antibody to E47 (clone G127-32; BD), 
goat polyclonal antibody to PARP-1 (sc-1561; Santa Cruz Biotechnology, Inc.), 
and mouse monoclonal antibody to -actin (A5316; Sigma-Aldrich). Filters 
were incubated with horseradish peroxidase–conjugated secondary antibodies. 
Bands  were  visualized  with  the  enhanced  chemiluminescence  system   
(GE Healthcare).
FISH analysis of E2A. FISH analysis was performed on enriched tumor 
cells using the specific DNA-probes spanning the E2A gene (RP11-690N6) 
and control probes for 19qter (D19S989; Kreatech) to judge the copy num-
ber of chromosome 19. Hybridization, detection, dual color image acquisi-
tion, and image analysis were performed as previously described (Schröck 
and Padilla-Nash, 2000).
RNA  preparation,  semiquantitative,  and  real-time  PCR  analy-
ses.  Total  RNA  was  prepared  using  the  RNeasy  kit  (QIAGEN).  First 
strand  cDNA-synthesis  was  performed  by  use  of  the  first-strand  cDNA 
synthesis  kit  (AMV;  Roche)  adding  oligo-p(dT)15  primer  according  to 
the  manufacturer’s  recommendation.  For  semiquantitative  PCR  analyses 
primers were as follows: GAPDH, sense (s) 5-ATGCTGGCGCTGA-
GTAC-3 and antisense (as) 5-TGAGTCCTTCCACGATAC-3; E2A, s 
5-CACCCTCCCTGACCTGTCT-3 and as 5-GGAGCTGAAAGCAC-
CATCTG-3;  RGS16,  s  5-TGGAGAGAGTCGTTCGACCTG-3  and 
as  5-TGTCCTCTTGCACTTGCTTTGC-3;  RASSF4,  s  5-GGTG-
GGGATGACTTTCAATG-3  and  as  5-GTGGCTTCCAAGCTAT-
GCTC-3;  BCL2L11  s  5-GGGTGACTGGAGAGCTCATT-3  and  as 
5-AAAGCACAGGAAGTTGCACA-3; DTX1, s 5-CTGGTCACAG-
CATCAGGCTA-3  and  as  5-GGTCTTGTGGTGGATCTCGT-3. 
Real-time PCR analyses were performed using Power SYBR Green Master-
mix and the ABI StepOnePlus real-time PCR system (Applied Biosystems). 
Three technical replicates were performed for each reaction and specificity 
of PCR products was confirmed by melting curve analysis and subsequent 
agarose  gel  electrophoresis.  Relative  expression  values  were  determined   
using the 2-Ct method. Calculations were done with the StepOnePlus soft-
ware, taking into account the determined primer efficiency of each primer 
set used. Primers used for real-time PCR analyses were as follows: myc, s 
5-TCAAGAGGTGCCACGTCTCC-3  and  as  5-TCTTGGCAGCAG-
GATAGTCCTT-3;  CDK6,  s  5-GGCTGTGTGAACCAGCCCAAG-3 
and  as  5-TGGCCAGGCCTAGACAGGCA-3;  DTX1,  s  5-TCAG-
GCTACGAGGGCGTGCT-3 and as 5-CCACGAGGCACAGCAG-
GTGG-3;  BIK,  s  5-AGCTCCTGGAACCCCCGACC-3  and  as 
5-CGCAGGGCCAATGCGTCACT-3; MAL, s 5-GGTGGGAAGTGGC-
GACCGTG-3 and as 5-ACAAGATGGGGCGCTCGGGA-3; RASSF4, 
s  5-TTGGGCGTGGAAGTCCCCCA-3  and  as  5-AGGCGCTGCAG-
CATCGTCAG-3; BCL2L11, s 5-TGCCAGCCCTGGCCCTTTTG-3 
and as 5-GGCCTGGCAAGGAGGACTTGG-3; RGS16, s 5-TCAGCC-
GCCTCTGCCACTCT-3  and  as  5-CGGCTGGCTTCCTCACT-
GCC-3;  RASA4,  s  5-TTTGGCGGCTCGCACGTCAT-3  and  as 
5-CACCTTCCGCAGCGCAGACA-3;  DAB2IP,  s  5-CTGTGTG-
CAGCCCTCGAGCC-3 and as 5-GAGGTGCTCGTTGTCCCCGC-3; 
TBP,  s  5-CAGGAGCCAAGAGTGAAGAACA-3  and  as  5-AGCTG-
GAAAACCCAACTTCTGT-3;  GAPDH,  s  5-CTCTGCTCCTCCT-
GTTCGAC-3  and  as  5-TTAAAAGCAGCCCTGGTGAC-3;  TaqMan 
Gene Expression Assays Hs01012686_m1 (E47), Hs0102692_g1 (E12/E47), 
and Hs03929097_g1 (GAPDH). For statistical analyses, independent Student’s 
t tests were used. All PCR products were verified by sequencing.
Direct sequencing of E2A coding regions. All 18 coding exons of E2A 
(E12 and E47) were amplified from 10–20 ng of genomic DNA isolated 
from enriched tumor cells using AccuPrime GC-Rich Polymerase (Invitro-
gen) according to the manufacturer’s recommendations. PCR products were 
directly sequenced by using the BigDye Terminator V1.1 cycle sequencing 
kit (Applied Biosystems) and subsequent analysis on an ABI PRISM 310 
Genetic Analyzer. Primer sequences for amplification and sequencing were as 
follows: Exon 1, s 5-CCTCCCTGTTTCTCCCTGTC-3 and as 5-GAA-
AACCTTCCCGTGAACTG-3; Exon 2, s 5-TGTAGGGTTTGGTT-
TGCCAC-3 and as 5-CACTGTCTTCAACAGACCCTTG-3; Exon 3, 
s 5-AGGTTTGCCCCTGAGATGAT-3 and 3 as 5-CAGGACTCA-
AACCCATGTCC-3;  Exon  4,  s  5-GGACATGGGTTTGAGT-
CCTG-3  and  as  5-GTGAACGCTGGGGACTTG-3;  Exon  5,  s 
5-CCCTCAGGATGTTCCTTGGG-3 and as 5-GAGAGGGTGGGT-
GACAGATTTG-3; Exon 6, s 5-AACAGCCTGGGGTCTGGATG-3 1592 Loss of E2A in human lymphoma | Steininger et al.
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